AP
WST icon

Advisor Partners’s West Pharmaceutical WST Stock Holding History

Advisor Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1.07M Buy
3,555
+1,061
+43% +$345K 0.08% 278
2022
Q1 		$1.02M Buy
2,494
+127
+5% +$49.7K 0.06% 295
2021
Q4 		$1.11M Buy
2,367
+217
+10% +$93.4K 0.07% 281
2021
Q3 		$913K Sell
2,150
-124
-5% -$52.3K 0.06% 296
2021
Q2 		$817K Sell
2,274
-114
-5% -$37.7K 0.05% 348
2021
Q1 		$673K Buy
2,388
+52
+2% +$14.9K 0.05% 393
2020
Q4 		$662K Buy
2,336
+199
+9% +$55.8K 0.05% 362
2020
Q3 		$587K Buy
2,137
+129
+6% +$34.1K 0.05% 342
2020
Q2 		$456K Buy
2,008
+192
+11% +$37.7K 0.04% 392
2020
Q1 		$276K Buy
1,816
+160
+10% +$24.6K 0.03% 463
2019
Q4 		$260K Sell
1,656
-3
-0.2% -$437 0.03% 533
2019
Q3 		$235K Buy
+1,659
New +$228K 0.03% 567

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Advisor Partners's WST Position: Q2 2022 in Review

Advisor Partners increased its West Pharmaceutical (WST) stake by 43% in Q2 2022, buying an estimated $345K and bringing the position to 3,555 shares worth $1.07M. The position accounts for 0.08% of the portfolio, ranked #278.

Advisor Partners first reported a position in WST in Q3 2019 and has held it in 12 quarters since. The position peaked at $1.11M in Q4 2021. 655 funds tracked by Wall St. Rank hold WST as of Q2 2022.

  • Advisor Partners held 3,555 shares of West Pharmaceutical worth $1.07M as of Q2 2022.
  • Advisor Partners bought 1,061 West Pharmaceutical shares in Q2 2022, an estimated $345K.
  • West Pharmaceutical made up 0.08% of Advisor Partners's portfolio in Q2 2022, its #278 holding.
  • Advisor Partners first reported a position in West Pharmaceutical in Q3 2019 and has held it in 12 quarters since.
  • Advisor Partners's West Pharmaceutical position peaked at $1.11M in Q4 2021.
  • 655 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.